Kura Oncology (KURA) vs Olema Oncology (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kura Oncology (KURA) has outperformed Olema Oncology (OLMA) over the past year, losing 38.1% versus a loss of 69.7%. Over five years, KURA leads with a -50.7% price change compared with -66.4% for OLMA. Kura Oncology is the larger company by market cap ($634.9 million vs $615.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KURA | OLMA |
|---|---|---|
| Share price | $6.91 | $7.02 |
| Market cap | $634.88M | $615.00M |
| 1-day change | -5.99% | -1.82% |
| YTD return | -33.49% | -71.92% |
| 1-year return | -38.14% | -69.70% |
| 5-year return | -50.66% | -66.36% |
| EPS (TTM) | $-3.30 | $-2.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.48M | — |
| Revenue growth (YoY) | +25.24% | — |
| Net income (latest FY) | $-278.67M | $-162.45M |
| Operating margin | -449.94% | — |
| Net margin | -412.95% | — |
| 52-week high | $13.90 | $36.26 |
| 52-week low | $6.75 | $6.24 |
| Distance from 52-week high | -50.29% | -80.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +357.60% | +405.70% |
| Average volume | 2.10M | 1.27M |
| Shares outstanding | 91.88M | 87.61M |
| Employees | 260 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed OLMA by 31.6 percentage points over the past year.
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
About Olema Oncology
OLMA stock →Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
KURA vs OLMA FAQ
Which is bigger, Kura Oncology or Olema Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $615.00M for Olema Oncology (OLMA).
Which stock has performed better over the past year, KURA or OLMA?
KURA returned -38.14% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Kura Oncology and Olema Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.